Close-up of a Nepali woman’s face with active acne breakouts, including red inflammatory papules, pustules, and scarring on her cheek and jawline.

October 24, 2026

What New Research Reveals About Acne Causes and Future Treatments

In dermatology practice, acne vulgaris is recognized as a chronic, multifactorial inflammatory disorder of the pilosebaceous unit that over-the-counter cleansers alone rarely resolve. Rather...

Young Nepali woman looking concerned at fallen hair in her hand, with text promoting a root cause hair loss checkup at Derma Clinic Kathmandu.

October 6, 2026

Hair Loss Blood Test Packages for Women At Derma Clinic

Are you experiencing sudden hair shedding, a widening hair part, or unexplained thinning? Shampoos and topical serums can only do so much if the...

Derma Clinic Kathmandu new opening hours infographic showing 9 AM to 7 PM Sunday to Friday with walk-in and appointment details

September 19, 2026

Derma Clinic Kathmandu New Opening Hours: 9 AM to 7 PM

We are thrilled to announce that Derma Clinic in Kathmandu is extending its operating hours. To better serve our patients and fit into your...

August 9, 2026

Confidential STD Testing in Kathmandu | Derma Clinic

Update to: Woman with melasma patches after exercise showing vascular flushing and skin pigmentation.

August 7, 2026

Does Exercise Worsen Melasma? Heat, Sweating & Flushing

If you suffer from melasma, you likely already know that sunlight is one of the most important environmental triggers. But what happens when you...

A detailed scientific visualization illustrating a 3D molecule of CAS Registry Number 2260696-63-5, labeled as 'active chemical entity.' The molecule is embedded within and activating a hair follicle stem cell metabolic pathway. A glowing 'Telogen to Anagen Switch' and 'Stem Cell Activation via MPC Inhibition' diagram is included. Crucially, a translucent, clear gel structure is visualized surrounding the molecule, specifically labeled 'PROPRIETARY TOPICAL VEHICLE (PHARMACEUTICAL FORMULATION),' which differentiates a finalized drug product from unregulated research chemicals (labeled separately as 'Raw JXL069/Unregulated Raw active entity'). Modern medical laboratory equipment is visible in the blurred background.

August 4, 2026

WHO Listing Links JXL069 to PP405 (Suvomipic)

Medical Reviewer: Dr. Utsav Sharma, Consultant Dermatologist PP405 topical gel is currently an investigational 0.05% formulation in clinical trials for androgenetic alopecia. It is...

Articles